Provided by Tiger Fintech (Singapore) Pte. Ltd.

AKESO

98.900
-1.100-1.10%
Volume:15.53M
Turnover:1.55B
Market Cap:88.81B
PE:-153.66
High:105.500
Open:105.000
Low:98.000
Close:100.000
Loading ...

Ivonescimab Receives Nmpa Approval for First-Line Treatment of Pd-L1-Positive Nsclc, Based on Breakthrough Head to Head Phase Iii Trial Demonstrating Superior Efficacy Over Pembrolizumab

THOMSON REUTERS
·
Yesterday

US FDA Approves Nasopharyngeal Carcinoma Drug

MT Newswires Live
·
25 Apr

BRIEF-Akeso Says FDA Approved Anniko (Penpulimab-Kcqx, Pd-1) In Two Indications

Reuters
·
25 Apr

Akeso Announces FDA Approval for Penpulimab-Kcqx in Two Bla Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma

THOMSON REUTERS
·
25 Apr

Akeso - FDA Approved Anniko (Penpulimab-Kcqx, Pd-1) in Two Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma

THOMSON REUTERS
·
25 Apr

FDA: on April 23, Approves Penpulimab-Kcqx for Non-Keratinizing Nasopharyngeal Carcinoma

THOMSON REUTERS
·
25 Apr

HK Movers | Biotech Stocks Jump With ImmuneOnco up 10%

Tiger Newspress
·
24 Apr

Akeso's Lung Cancer Drug Meets Primary Endpoints in China Phase 3 Trial; Shares Rise 5%

MT Newswires Live
·
23 Apr

HK Movers | Biotech Stocks Rally With Zai Lab up 8%

Tiger Newspress
·
23 Apr

Ivonescimab in Combination With Chemotherapy Demonstrates Statistically Significant and Strongly Positive Results in First-Line Treatment of Squamous Non-Small Cell Lung Cancer (Sq-Nsclc) VS. Tislelizumab in Combination With Chemotherapy

THOMSON REUTERS
·
23 Apr

Akeso's NDA for Plaque Psoriasis Drug Gets China Nod

MT Newswires Live
·
22 Apr

BRIEF-Akeso Says NMPA Approved NDA Of Ebdarokimab, Il-12/Il-23

Reuters
·
21 Apr

Akeso - Nmpa Approved Nda of Ebdarokimab, Il-12/Il-23

THOMSON REUTERS
·
21 Apr

BRIEF-Akeso Ebdarokimab Approved In China For Moderate - To - Severe Plaque Psoriasis

Reuters
·
18 Apr

Akeso: Ebdarokimab Approved in China for Moderate - to - Severe Plaque Psoriasis

THOMSON REUTERS
·
18 Apr

The Chinese CEO Who Believes Her Cancer Drug Can Beat Merck's Bestseller -- WSJ

Dow Jones
·
12 Apr

Chinese Biotech Stocks Outshine Tech Rally on Robust Earnings

Bloomberg
·
01 Apr

Akeso Swings to Loss in 2024

MT Newswires Live
·
31 Mar

Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape With Bispecific Antibodies

THOMSON REUTERS
·
31 Mar

Press Release: Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies

Dow Jones
·
31 Mar